Heparin Cofactor II Determination - Levels in Normals and Patients with Hereditary Antithrombin III Deficiency and Disseminated Intravascular Coagulation

Summary

A technique is described to completely remove antithrombin III (AT) from small amounts of human plasma by immunoaffinity chromatography on antibodies against human AT linked to Sepharose 4B. The level of heparin cofactor II (HCII) was not affected by the immunoadsorption. HCII activity was then determined by measuring the rate of human thrombin inhibition by 3 ways: a) activation with heparin in AT-free plasma, b) activation with dermatan sulfate in normal plasma and c) activation with dermatan sulfate in AT-free plasma. The normal range of HCII varied between 0.7-1.5 U/ml, as compared to a normal plasma pool containing by definition 1 U/ml. Highly significant correlations between assays as obtained from 40 normal plasmas proved the suitability of the 3 assays, although the progressive thrombin inhibition by AT, when not removed, contributed about one fifth to the thrombin inhibition by HCII in the presence of dermatan sulfate. There were also highly significant correlations between HCII activity and antigen, as determined by rocket immunoelectrophoresis using specific antibodies against HCII.

Levels of HCII and AT were examined in 7 patients with hereditary AT deficiency and 7 patients with disseminated intravascular coagulation (DIC). In hereditary AT deficiency, whereas the AT activity was reduced by half, levels of HCII activity and antigen were in the normal range. In DIC, a parallel decrease of HCII and AT suggests that HCII may participate in the inhibition of thrombin released during DIC and thus provides an inhibitor reserve, once the AT level becomes subnormally low.

Keywords

Heparin cofactor A - Antithrombin III - Disseminated intravascular coagulation - Antithrombin III deficiency - Immunoaffinity chromatography

• References

• 1 Tollefsen DM, Majerus DW, Blank MK. Heparin cofactor II. Purification and properties of a heparin dependent inhibitor of thrombin in human plasma. J Biol Chem 1982; 257: 2162-2169
• 2 Briginshaw GF, Shanberge JN. Separation and partial purification. Arch Biochem Biophys 1974; 161: 683-690
• 3 Wunderwald P, Schrenk WJ, Port H. Antithrombin BM from human plasma: an antithrombin binding moderately to heparin. Thromb Res 1982; 25: 177-191
• 4 Tollefsen DM, Pestka CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 1983; 258: 6713-6716
• 5 Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thrombos Diathes Haemorrh 1965; 13: 516-530
• 6 Van der Meer J, Stoepman-van Dalen EA, Jansen JM S. Antithrombin III deficiency in a Dutch Family. J Clin Pathol 1973; 26: 532-538
• 7 Marciniak E, Farley CH, Desimone PA. Familial thrombosis due to antithrombin III deficiency. Blood 1974; 43: 219-231
• 8 Carvalho A, Ellman L. Hereditary antithrombin III deficiency. Effect of antithrombin III deficiency on platelet function Am J Med 1976; 61: 179-183
• 9 ødegård OR, Abildgaard U. Antifactor X activity in thrombophilia. Studies in a family with AT-III deficiency Scand J Haematol 1977; 18: 86-90
• 10 Mackie M, Bennett B, Ogston D, Douglas AS. Familial thrombosis: inherited deficiency of-antithrombin III. Br Med J 1978; 1: 136-138
• 11 Sas G, Pepper DS, Cash JD. Further investigations on antithrombin in the plasma of patients with the abnormality of “antithrombin III Budapest”. Thrombos Diathes Haemorrh 1975; 38: 494-503
• 12 Tran TH, Bounameaux H, Bonded C, Honkanen H, Marbet GA, Duckert F. Purification and partial characterization of a hereditary abnormal antithrombin III fraction of a patient with recurrent thrombophlebitis. Thromb Haemostas 1980; 44: 87-91
• 13 Wolf M, Boyer C, Lavergne JM, Larrieu MJ. A new familial variant of antithrombin III: “Antithrombin III Paris”. Br J Haematol 1982; 51: 285-295
• 14 SØrensen PJ, Sas G, Peto I, Blasko G, Kremmer T, Samu A. Distinction of two pathologic antithrombin III molecules: antithrombin III “Aarlborg” and antithrombin III “Budapest”. Thromb Res 1982; 26: 211-219
• 15 Barbui T, Finazzi G, Rodeghiero F, Dini E. Immunoelectrophoretic evidence of a thrombin-induced abnormality in a new variant of hereditary dysfunctional antithrombin III (AT III “Vicenza”). Br J Haematol 1983; 54: 561-565
• 16 Bick RL, Bick MD, Fekete LF. Antithrombin III patterns in disseminated intravascular coagulation. Am J Clin Pathol 1980; 73: 577-583
• 17 Spero JA, Lewis JH, Hasiba U. Disseminated intravascular coagulation. Findings in 346 patients Thromb Haemostas 1980; 43: 28-33
• 18 Kierulf P, Aasen AO, Aune S, Godal HC, Rund TE, Vaage J. Chromogenic peptide substrate assays in patients with multiple trauma. Acta Chir Scand 1982; 509 Suppl 69-72
• 19 Lämmle B, Tran TH, Ritz R, Duckert F. Plasma prekallikrein, factor XII, antithrombin III, C₁-inhibitor and α₂-macroglobulin in critically ill patients with suspected disseminated intravascular coagulation (DIC).. Am J Clin Pathol. 1984 (in press)
• 20 Tran TH, Marbet GA, Duckert F. Rabbit antibodies against the procoagulant activity (VIII :C) of human factor VIII. Some theoretical and practical considerations on the human factor VIII molecule using heterologous antibodies. Thromb Haemostas 1981; 46: 699-705
• 21 Cuatrecasas P. Protein purification by affinity chromatography. Derivatizations of agarose and polyacrylamide beads J Biol Chem 1970; 245: 3059-3065
• 22 Tran TH, Lämmle B, Zbinden B, Duckert F. Thrombin inhibition by antithrombin III (AT) and heparin cofactor II (HCII) in the presence of heparin. Improved purification of HCII. Blut 1984 48. in press (Abstr)
• 23 Griffith MJ, Carraway T, White GC, Dombrose FA. Heparin cofactor activities in a family with hereditary antithrombin III deficiency: evidence for a second heparin cofactor in human plasma. Blood 1983; 61: 111-118
• 24 Busch C, Owen WG. Identification in vitro of an endothelial cell surface cofactor for antithrombin III. Parallel studies with isolated perfused rat hearts and microcarrier cultures of bovine endothelium. J Clin Invest 1982; 69: 726-729